Helicore Biopharma
Facts
as of Nov 17, 2026Long-Acting Medicines to Transform Metabolic Health. Pioneering long-acting antibody conjugates to deliver quarterly administered, best-in-category therapies for obesity and cardiometabolic disease.
- Legal name
- Helicore, LLC
- Headquarters
- Southbury, United States
- Founded
- 2020
- Employees
- 1-10estimated range
- Register numbers
- NAME helicore llc
- Official records
- SEC CIK 1810144
- Website
- helicore.com
These are the key facts about Helicore Biopharma on Alion as of Nov 17, 2026. Helicore Biopharma is headquartered in Southbury, United States. It was founded in 2020. The latest round is Venture - Series Unknown of $2M, announced in 2020.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Helicore, LLC
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Southbury United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$2MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$2M
Sources: funding announcements, grant and company registers
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Mar 25, 20252025
Press release · The Manila Times
media576066
Jan 28, 20252025
News · YahooFinance
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025 Building on existing validation of GIP pathwa…
Jan 27, 20252025
News · bioworld.com
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists f…
Sources: the outlets named on each headline, each story once
